Figure 1.
Kaplan Meier curves for progression free survival (primary endpoint) of patients with metastatic pancreatic cancer treated with gemcitabine plus erlotinib with with or without cixutumumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.